Advertisement

Supportive Care in Cancer

, Volume 25, Issue 7, pp 2179–2185 | Cite as

Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash

  • Jesper Grau EriksenEmail author
  • Inger Kaalund
  • Ole Clemmensen
  • Jens Overgaard
  • Per Pfeiffer
Original Article

Abstract

Purpose

Cetuximab inhibits the epidermal growth factor receptor (EGFR), and papulopustular eruptions is a frequent side effect. Vitamin K3 (menadione) has preclinically shown to be a potential activator of the EGFR by phosphorylating the receptor (pEGFR). The present randomised study investigated the effect of a vitamin K3 cream on cetuximab-induced rash.

Materials and methods

Thirty patients were included in this double-blinded placebo-controlled trial. Patients receiving cetuximab 500 mg/m2 every second week plus chemotherapy for metastatic cancer were included. In each patient, vitamin K3 cream and placebo were applied twice daily on two separate areas of the skin of minimum 10 × 10 cm for up to 2 months. Papulopustular eruptions were evaluated clinically and monitored by clinical photos. Skin biopsies, from ten patients taken before and after 1 month of treatment from each treatment area, were stained for EGFR and pEGFR.

Results

Application of vitamin K3 cream twice daily during treatment with cetuximab did not reduce the number of papulopustular eruptions, and this was independent of the use of systemic tetracycline. No significant changes in the staining of EGFR or pEGFR were observed in the skin of the vitamin K3-treated area compared to the placebo area.

Conclusion

The present data do not support any clinical or immunohistochemical benefit of using vitamin K3 cream for cetuximab-induced rash.

Keywords

Skin toxicity Rash EGFR-inhibitor Cetuximab Phase II 

Notes

Acknowledgements

We acknowledge the skilled work of Mrs. Inger Marie Horsman, Inger Marie Thuesen and Dorthe Grand, conducting the animal experiments at Dept. of Experimental Clinical Oncology, Aarhus, Denmark.

The study was supported by a grant from “A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal; Fondet til Lægevidenskabens Fremme” and Merck KGaA, Darmstadt, Germany. The study was designed, conducted and the data analysed independently of the company. The authors are fully responsible for the content of this manuscript, and the views and opinions described in the publication reflect solely those of the authors.

Compliance with ethical standards

Conflicts of interest

The study was supported by a grant from a public foundation “A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal; Fondet til Lægevidenskabens Fremme” and the commercial company Merck KGaA, Darmstadt, Germany. The study was designed, conducted and the data analysed independently of the company. The authors are fully responsible for the content of this manuscript, and the views and opinions described in the publication reflect solely those of the authors. None of the authors have any conflicts of interest to report related to the present study. The authors allow the journal to review the data if requested.

Supplementary material

520_2017_3623_MOESM1_ESM.docx (4.2 mb)
ESM 1 (DOCX 4334 kb)

References

  1. 1.
    Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337–345CrossRefPubMedGoogle Scholar
  2. 2.
    Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567–578CrossRefPubMedGoogle Scholar
  3. 3.
    Pfeiffer P, Qvortrup C, Eriksen JG (2007) Current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene 26(25):3661–3678CrossRefPubMedGoogle Scholar
  4. 4.
    Su X, Lacouture ME, Jia Y, Wu S (2009) Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncology 77(2):124–133CrossRefPubMedGoogle Scholar
  5. 5.
    Robert C, Soria JC, Spatz A, Le CA, Malka D, Pautier P et al (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6(7):491–500CrossRefPubMedGoogle Scholar
  6. 6.
    Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC (2006) Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55(4):657–670CrossRefPubMedGoogle Scholar
  7. 7.
    Li T, Perez-Soler R (2009) Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 4(2):107–119CrossRefPubMedGoogle Scholar
  8. 8.
    Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW (2007) Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 56(2):317–326CrossRefPubMedGoogle Scholar
  9. 9.
    Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6(10):803–812CrossRefPubMedGoogle Scholar
  10. 10.
    Ocvirk J, Heeger S, McCloud P, Hofheinz RD (2013) A review of the treatment options for skin rash induced by EGFR-targeted therapies: evidence from randomized clinical trials and a meta-analysis. Radiol Oncol 47(2):166–175CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Perez-Soler R, Zou Y, Li T, Ling YH (2011) The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab. Clin Cancer Res 17(21):6766–6777CrossRefPubMedGoogle Scholar
  12. 12.
    Ocvirk J (2010) Management of cetuximab-induced skin toxicity with the prophylactic use of topical vitamin K1 cream. Radiol Oncol 44(4):265–266CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Pinta F, Ponzetti A, Spadi R, Fanchini L, Zanini M, Mecca C et al (2014) Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer. Clin Colorectal Cancer 13(1):62–67CrossRefPubMedGoogle Scholar
  14. 14.
    Tomkova H, Pospiskova M, Zabojnikova M, Kohoutek M, Serclova M, Gharibyar M et al (2013) Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis. J Eur Acad Dermatol Venereol 27:514–519CrossRefPubMedGoogle Scholar
  15. 15.
    Eriksen JG, Steiniche T, Alsner J, Askaa J, Overgaard J (2004) The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 58:561–566CrossRefPubMedGoogle Scholar
  16. 16.
    Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB et al (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19(8):1079–1095CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Abdelmohsen K, Patak P, Von MC, Melchheier I, Sies H, Klotz LO (2004) Signaling effects of menadione: from tyrosine phosphatase inactivation to connexin phosphorylation. Methods Enzymol 378:258–272CrossRefPubMedGoogle Scholar
  18. 18.
    Beier JI, Von MC, Sies H, Klotz LO (2006) Activation of ErbB2 by 2-methyl-1,4-naphthoquinone (menadione) in human keratinocytes: role of EGFR and protein tyrosine phosphatases. FEBS Lett 580(7):1859–1864CrossRefPubMedGoogle Scholar
  19. 19.
    Lopes LB, Speretta FF, Bentley MV (2007) Enhancement of skin penetration of vitamin K using monoolein-based liquid crystalline systems. Eur J Pharm Sci 32(3):209–215CrossRefPubMedGoogle Scholar
  20. 20.
    Camarasa JG, Barnadas M (1982) Occupational dermatosis by vitamin K3 sodium bisulphite. Contact Dermatitis 8(4):268CrossRefPubMedGoogle Scholar
  21. 21.
    Wehler TC, Graf C, Mohler M, Herzog J, Berger MR, Gockel I et al (2013) Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective. J Cancer Res Clin Oncol 139(10):1667–1672CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Perez-Soler R, Zou Y, Li T, Ling YH (2013) Retraction: the phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab. Clin Cancer Res 19:4901–4902CrossRefPubMedGoogle Scholar
  23. 23.
    Pfeiffer P, Nielsen D, Bjerregaard J, Qvortrup C, Yilmaz M, Jensen B (2008) Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol 19(6):1141–1145CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Jesper Grau Eriksen
    • 1
    Email author
  • Inger Kaalund
    • 1
  • Ole Clemmensen
    • 2
  • Jens Overgaard
    • 3
  • Per Pfeiffer
    • 1
  1. 1.Department of OncologyOdense University HospitalOdense CDenmark
  2. 2.Department of Clinical PathologyOdense University HospitalOdenseDenmark
  3. 3.Department Of Experimental Clinical OncologyAarhus University HospitalAarhusDenmark

Personalised recommendations